Literature DB >> 1985538

Liver transplantation in children.

R W Busuttil1, P Seu, J M Millis, K M Olthoff, J R Hiatt, A Milewicz, B Nuesse, G el-Khoury, D Raybould, A Nyerges.   

Abstract

Although liver transplantation is now accepted as the ideal therapy for end-stage liver disease, relatively few centers have gained a large experience in children, and good results have been elusive. Technical difficulty and a high incidence of graft failure are among the obstacles to success. At the University of California at Los Angeles, 39% of our liver transplants are in the patients who are younger than 18 years. We have analyzed our experience with 103 patients to emphasize factors important to a favorable outcome with the procedure. One hundred twenty-three transplants were performed in 103 children (mean age, 5.2 years; 48% younger than 3 years). No reduced-size grafts were used. Scrupulous attention to technical details of the vascular reconstruction, including frequent use of the supraceliac aorta of the recipient and interrupted suture techniques, ensured construction of sound hepatic artery and portal vein anastomoses at the first operation. Preoperative exchange transfusions were used if the prothrombin time was prolonged beyond 7 seconds, resulting in an average blood loss of only 3.3 volumes. Cyclosporine dosage was maintained in the high therapeutic range for the first 4 weeks, and anti-T-cell antibody (OKT3) was used for rejection (38%). Amphotericin prophylaxis was used for biliary atresia patients with multiple previous operations. Eighty-two of one hundred three patients (80%) are alive. There were no intraoperative deaths. Actuarial survival rates at 6 months, 1 year, and 5 years are 80%, 79%, and 77%, respectively. Survival of patients who underwent transplantation at age less than 1 year is 65% versus 85% at age more than 1 year (p = 0.08). Retransplantation was performed in 19 patients (18%), with a survival rate of 58%. Hepatic artery thrombosis, the most frequent technical complication, occurred in only 16 patients (13%). Survival rates of ABO identical-match versus nonidentical-match grafts were 96% and 60%, respectively (p = 0.02). Graft survival was only 47% if more than one steroid cycle was needed, compared to 75% survival with OKT3 treatment. Despite impairment of renal function (glomerular filtration rate [GFR] less than 80 cc/kg/min) in 54% of patients and hypertension requiring therapy in 27%, 90% of the children demonstrated enhancement of growth, development, and functional status. The following conclusions were made. (1) Pediatric liver transplantation is the treatment of choice for all types of end-stage liver disease and should be considered early. (2) Factors that enhance survival include technical precision, aggressive retransplantation, antifungal chemoprophylaxis and therapy, and judicious immunosuppression with use of OKT3 for rejection.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1991        PMID: 1985538      PMCID: PMC1358310          DOI: 10.1097/00000658-199101000-00009

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  24 in total

1.  HOMOTRANSPLANTATION OF THE LIVER IN HUMANS.

Authors:  T E STARZL; T L MARCHIORO; K N VONKAULLA; G HERMANN; R S BRITTAIN; W R WADDELL
Journal:  Surg Gynecol Obstet       Date:  1963-12

2.  A randomized clinical trial comparing OKT3 and steroids for treatment of hepatic allograft rejection.

Authors:  A B Cosimi; S I Cho; F L Delmonico; M M Kaplan; R J Rohrer; R L Jenkins
Journal:  Transplantation       Date:  1987-01       Impact factor: 4.939

3.  OKT3 in the reversal of acute hepatic allograft rejection.

Authors:  C O Esquivel; J J Fung; B Markus; S Iwatsuki; R D Gordon; L Makowka; J W Marsh; A G Tzakis; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

4.  Orthotopic homotransplantation of the human liver.

Authors:  T E Starzl; C G Groth; L Brettschneider; I Penn; V A Fulginiti; J B Moon; H Blanchard; A J Martin; K A Porter
Journal:  Ann Surg       Date:  1968-09       Impact factor: 12.969

5.  Branch patch for arterialization of hepatic grafts.

Authors:  W J Quinones-Baldrich; L Memsic; K Ramming; J Hiatt; R W Busuttil
Journal:  Surg Gynecol Obstet       Date:  1986-05

6.  Pediatric liver transplantation at UCLA.

Authors:  J R Hiatt; M E Ament; W J Berquist; J F Brems; J E Brill; J O Colonna; G el Khoury; W J Quinones; K P Ramming; J H Vargas
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

Review 7.  Evolution of liver transplantation.

Authors:  T E Starzl; S Iwatsuki; D H Van Thiel; J C Gartner; B J Zitelli; J J Malatack; R R Schade; B W Shaw; T R Hakala; J T Rosenthal; K A Porter
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

8.  Progress in the treatment of biliary atresia.

Authors:  R Ohi; M Hanamatsu; I Mochizuki; T Chiba; M Kasai
Journal:  World J Surg       Date:  1985-04       Impact factor: 3.352

9.  Pediatric liver transplantation.

Authors:  T E Starzl; C Esquivel; R Gordon; S Todo
Journal:  Transplant Proc       Date:  1987-08       Impact factor: 1.066

10.  Analysis of patients with biliary atresia coming to liver transplantation.

Authors:  B J Pettitt; B J Zitelli; M I Rowe
Journal:  J Pediatr Surg       Date:  1984-12       Impact factor: 2.545

View more
  23 in total

Review 1.  Who needs a liver transplant? (new disease specific indications).

Authors:  A Baker; A Dhawan; N Heaton
Journal:  Arch Dis Child       Date:  1998-11       Impact factor: 3.791

2.  Orthotopic liver transplantation in liver-based metabolic disorders.

Authors:  A P Mowat
Journal:  Eur J Pediatr       Date:  1992       Impact factor: 3.183

Review 3.  Liver transplantation.

Authors:  J Chiyende; A P Mowat
Journal:  Arch Dis Child       Date:  1992-09       Impact factor: 3.791

4.  The use of liver grafts infested with Clonorchis sinensis for orthotopic liver transplantation.

Authors:  C K Yeung; J K Ho; W Y Lau; K H Lee; A K Li
Journal:  Postgrad Med J       Date:  1996-07       Impact factor: 2.401

5.  FK 506 versus cyclosporine in pediatric liver transplantation.

Authors:  A G Tzakis; J Reyes; S Todo; M Green; T Ohya; A Jain; K Abu-Elmagd; M Alessiani; J J Fung; T E Starzl
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

Review 6.  Intravenous volume replacement: which fluid and why?

Authors:  L Huskisson
Journal:  Arch Dis Child       Date:  1992-05       Impact factor: 3.791

Review 7.  Split-liver transplantation. The Paul Brousse policy.

Authors:  D Azoulay; I Astarcioglu; H Bismuth; D Castaing; P Majno; R Adam; M Johann
Journal:  Ann Surg       Date:  1996-12       Impact factor: 12.969

8.  Orthotopic liver transplantation for congenital biliary atresia. An 11-year, single-center experience.

Authors:  J A Goss; C R Shackleton; K Swenson; N L Satou; B J Nuesse; D K Imagawa; M M Kinkhabwala; P Seu; J S Markowitz; S M Rudich; S V McDiarmid; R W Busuttil
Journal:  Ann Surg       Date:  1996-09       Impact factor: 12.969

Review 9.  Quality of life after orthotopic liver transplantation in children. An overview of physical, psychological and social outcome.

Authors:  E M Sokal
Journal:  Eur J Pediatr       Date:  1995-03       Impact factor: 3.183

10.  Liver transplantation in infants younger than 1 year of age.

Authors:  P M Colombani; F G Cigarroa; K Schwarz; B Wise; W E Maley; A S Klein
Journal:  Ann Surg       Date:  1996-06       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.